Correct classification of nearly every patient with bad prognosis (relapse or death) at TNM stage II when CEA and CA 72.4 are used altogether. »
11/12/13

No support of the hypothesis that aberrations of RRM1 or RRM2B associated with an altered clinical outcome following chemotherapy. »
11/12/13

The present study focused on the prognostic roles of PIK3CA and PIK3R1 genes and additional PI3K pathway-associated genes in breast cancer. »
11/14/13

Resistance to platinum-based chemotherapy remains a major impediment in the treatment of serous »
11/16/13

Mammosphere-based negative selection shRNAi screening system suitable to analyse the involvement of thousands of genes in the survival of cells with cancer stem cell properties. »
11/14/13

Increasing evidence suggest that ubiquitin-proteasome system (UPS) plays a key role in tumorigenesis. HERC4 is a recently identified ubiqutin ligase. »
11/14/13

Cell fate at the time of cell division may explain how CSCs are maintained in tumors. »
11/15/13

Adjuvant immunotherapy that targets NK cells in M-LN for activation may improve treatment of sentinel LN-positive melanoma patients. »
11/15/13

hNoxin is a DNA damage-induced anti-apoptotic protein and potential therapeutic target in cancer. »
04/18/13

Pt-(GpG) intrastrand crosslinks are the major DNA adducts induced by platinum-based anticancer drugs. In the cell lines and mouse models, the persistence of these lesions correlates significantly with cell damage. Here we studied Pt-(GpG) DNA adducts in circulating tumour cells (CTC) treated with cisplatin in medium upfront to systemic therapy from patients with advanced non-small-cell lung cancer (NSCLC). »
03/16/13